Standard BioTools Inc
LAB
Market Cap$686.63M
Close$
Share Statistics
| Market cap | $686.63 Million |
|---|---|
| Enterprise Value | $584.61 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.94 |
| Beta | 1.58 |
| Outstanding Shares | 372,331,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.81 |
|---|---|
| PEG | 30.48 |
| Price to Sales | - |
| Price to Book Ratio | 1.05 |
| Enterprise Value to Revenue | 3.45 |
| Enterprise Value to EBIT | -4.26 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Standard BioTools Inc
627 employees
CEO: Stephen Linthwaite Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-om...